The Face Recognition Company (FRC) produces 90%+ accurate face recognition solution. In 2016, the company came up with the objective to develop the most accurate and cost-effective facial recognition solution. This technology is suitable for commercial applications or crime and other security uses. Additionally, the FRC's go-to-market strategy incorporates working through large integrators/partners/approved installers, eight of which are ready to promote and install its product to their own customer base. The FRC team has technically developed this solution by combining 100 years of experience in facial recognition. In June 2018, FRC had filed for two patents: first, ‘Recognition of 3D Objects’ and second, 'Method of and System for Recognising a Human Face’. Where suitable, FRC has also set-up an EIS tax relief.
days to go:
Expired
investment:
£215,600
Ancon is designed to detect trace elements of things such as explosives, drugs and chemical weapons in the air. Ancon manufactures equipment and components that are up to 10,000 times more sensitive then anything else on the market.
days to go:
Expired
investment:
£1,043,525
Arcade is an innovative provider of technology (patent pendinG) that empowers telecom carriers to offer life-changing gigabit broadband over existing networks, with rapid deployment and ROI in under a year. Their solutions enable gigabit speeds everywhere, complementing fiber strategies and avoiding extensive cable replacements.
days to go:
Expired
investment:
£350,000
ZOA Robotics build robots which have been inspired by nature. They are currently focusing on low-cost 4-legged systems for the transportation of materials on uneven ground. ZOA's founder has experience in the robotics industry and has already created impressive initial prototypes of the product.
days to go:
Expired
investment:
£188,300
Bodytrak is a wearable technology that monitors physiological activity such as heart rate and core body temperature. This real time data is analysed using cloud based technology and algorithms to supervisors or commanders so early action can be taken on the event of illness or injury.
days to go:
Expired
investment:
£1,123,119
Third Bladetec Bitcoin Mine is aiming to be the largest bitcoin mine in the UK. They are looking to raise £10million to fund the building and operations of the mine.
days to go:
Expired
investment:
£1,195,000
Zap and Go have created ultra fast technology for cordless and hand held devices by using Carbon-Ion technology which result in ultra-fast charging, taking 5 minutes or less. The technology is part derived from Oxford University and in part developed independently by Zap&Go's own scientists.
days to go:
Expired
investment:
£1,353,551
VoxSmart is a global mobile technology company focused on achieving compliance in a very heavy regulated industries such as finance and banking. VoxSmart software is embedded on the mobile device and allows the capturing and recording of all communications on that device
days to go:
Expired
investment:
£3,857,500
Kaleao has created simple, agile and flexible hardware and software systems which provide 10x more performance per unit of space and consumes 4x less energy. They maintain all promises of the hyperconvergence through the convergence of compute, storage and networking hardware whilst teamed with a full-featured and flexible software platform.
days to go:
Expired
investment:
£2,050,000
Ceryx Medical is a medical technological entity that is developing bioelectronics based on a unique, patent-protected, chip technology that can mimic nerve centres within the body called Central Pattern Generators (CPGs). CPGs help to control a range of autonomic or rhythmical processes within the body such as peristalsis, heart rate, and even walking. The Ceryx system resembles a traditional cardiac pacing device that holds a lot of promise in potentially alleviating incidences of heart failure leading to a therapeutic effect on patient health. In the UK, this is a day surgery procedure under local anaesthetic with a basic system costing around £3500. The device, therefore, offers a cost-effective, single procedure solution for this currently intractable disease. Treatment expenditures on heart failure cases in the EU amount to almost £35 billion. The Ceryx system is a potential disruptor in this segment and offers multiple potential applications. The company is targeting £500,000 as part of £1 million round. With the investment, the company aims to produce a data package that mimics those used to support 510k/NDA applications, as mandated by the US Food and Drug Administration (FDA), for current devices and drugs used to treat heart failure.
days to go:
Expired
investment:
Withheld
